Tag: Beta-carboline reversible MAO-A inhibitor (DYRK1A inhibitor)

  • Harmine

    Beta-carboline reversible MAO-A inhibitor (DYRK1A inhibitor)

    A beta-carboline alkaloid from Peganum harmala; a reversible MAO-A inhibitor and DYRK1A kinase inhibitor of interest in beta-cell biology.

    Abstract

    Harmine (7-methoxy-1-methyl-9H-pyrido[3,4-b]indole; CAS 442-51-3; molecular formula C13H12N2O; molecular weight 212.25) is a beta-carboline alkaloid from Peganum harmala and Banisteriopsis caapi. The compound is a reversible MAO-A inhibitor with similar selectivity profile to harmaline but with the additional well-characterized activity of DYRK1A kinase inhibition (IC50 approximately 30 nM). The DYRK1A activity has generated substantial interest in diabetes research: harmine and related DYRK1A inhibitors stimulate human pancreatic beta-cell proliferation in vitro and in vivo, a long-sought target for diabetes regenerative therapy. Phase 1 trials of derivatives are underway. Plasma half-life is approximately 1 to 3 hours. Used as a research probe for both ayahuasca pharmacology and beta-cell regenerative biology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.